The global pharmacovigilance (PV) or drug safety market is projected to grow from $8.6bn in 2024 to $22.4bn by 2032.
Fundamental drivers shaping this growth include:
- Growing levels of drug consumption with increasing complexity of drugs being developed
- Increasingly stringent regulatory mandates and complex compliance requirements
- Technological advancements driving efficiencies in the PV market
- Continued trend of outsourcing in the pharma services industry, including of PV services
Anticipating an exciting growth outlook, the demand for pharmacovigilance (PV) is poised to fuel increased M&A activity.
To learn more about the key M&A trends taking shape this year in the pharmacovigilance space, read our latest paper.
Originally Published 30 May 2024
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.